Cargando…

Author Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding

Detalles Bibliográficos
Autores principales:	Lua, Wai-Heng, Ling, Wei-Li, Yeo, Joshua Yi, Poh, Jun-Jie, Lane, David Philip, Gan, Samuel Ken-En
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050276/ https://www.ncbi.nlm.nih.gov/pubmed/30018413 http://dx.doi.org/10.1038/s41598-018-29097-z

Ejemplares similares

The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding
por: Lua, Wai-Heng, et al.
Publicado: (2018)

Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding
por: Ling, Wei-Li, et al.
Publicado: (2018)

A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2
por: Lua, Wai-Heng, et al.
Publicado: (2015)

Essentially Leading Antibody Production: An Investigation of Amino Acids, Myeloma, and Natural V-Region Signal Peptides in Producing Pertuzumab and Trastuzumab Variants
por: Ling, Wei-Li, et al.
Publicado: (2020)

Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and Trastuzumab
por: Samsudin, Firdaus, et al.
Publicado: (2020)

The role of Antibody Vκ Framework 3 region towards Antigen binding: Effects on recombinant production and Protein L binding
por: Su, Chinh Tran-To, et al.
Publicado: (2017)

Molecular Insights of Nickel Binding to Therapeutic Antibodies as a Possible New Antibody Superantigen
por: Su, Chinh Tran-To, et al.
Publicado: (2021)

Sagacity in antibody humanization for therapeutics, diagnostics and research purposes: considerations of antibody elements and their roles
por: Ling, Wei-Li, et al.
Publicado: (2020)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
por: Mortimer, Joanne E., et al.
Publicado: (2019)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Allosteric Effects between the Antibody Constant and Variable Regions: A Study of IgA Fc Mutations on Antigen Binding
por: Su, Chinh Tran-To, et al.
Publicado: (2018)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
por: Tóth, Gábor, et al.
Publicado: (2016)

Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer
por: Zekri, Jamal, et al.
Publicado: (2023)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Author Correction: Epitope-directed monoclonal antibody production using a mixed antigen cocktail facilitates antibody characterization and validation
por: Liew, Oi Wah, et al.
Publicado: (2021)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
por: Hughes, Juliana Bentes, et al.
Publicado: (2012)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
por: Nami, Babak, et al.
Publicado: (2019)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Trastuzumab Associated With Recurrent Severe Thrombocytopenia and Successful Use of Pertuzumab Monotherapy
por: Huff, Mallorie L, et al.
Publicado: (2022)

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023)

Augmenting recombinant antibody production in HEK293E cells: optimizing transfection and culture parameters
por: Heng, Zealyn Shi-Lin, et al.
Publicado: (2022)

Author Correction: Investigation of Cas9 antibodies in the human eye
por: Toral, Marcus A., et al.
Publicado: (2022)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Author Correction: Nuclei multiplexing with barcoded antibodies for single-nucleus genomics
por: Gaublomme, Jellert T., et al.
Publicado: (2020)

Author Correction: An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis
por: Krishnananthasivam, Shivankari, et al.
Publicado: (2023)

Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
por: Tran, Trung The, et al.
Publicado: (2023)

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2020)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Author Correction: Delayed production of neutralizing antibodies correlates with fatal COVID-19
por: Lucas, Carolina, et al.
Publicado: (2021)

Author Correction: Reconstructing antibody dynamics to estimate the risk of influenza virus infection
por: Tsang, Tim K., et al.
Publicado: (2023)

Variable-heavy (VH) families influencing IgA1&2 engagement to the antigen, FcαRI and superantigen proteins G, A, and L
por: Ling, Wei-Li, et al.
Publicado: (2022)

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
por: Barrett, Jordan R., et al.
Publicado: (2021)

Enrichment and Liquid Chromatography–Mass Spectrometry Analysis of Trastuzumab and Pertuzumab Using Affimer Reagents
por: Olaleye, Oladapo, et al.
Publicado: (2021)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
por: Thouvenin, Laure, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0jivof2lnqvr9re140ge9c4ncf